Following publication of the data presented by von Minckwitz and colleagues \[[@B1]\] it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 μg/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 μg/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table [2](#T1){ref-type="table"} overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table [2](#T1){ref-type="table"} were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table [2](#T1){ref-type="table"} overleaf).

Figures and Tables
==================

###### 

Study summary

  Patient   Dose level (μg/kg)   Course of therapy   Toxicities ≥ grade 1                        Dose-limiting toxicity   Neutralizing antibodies   Clinical response
  --------- -------------------- ------------------- ------------------------------------------- ------------------------ ------------------------- -------------------
  N01       2                    According to plan   GGT grade 2                                 No                       No                        Progression
  U01       2                    Stopped on day 10   Cholestasis due to liver metastasis^a^      No                       n.d.                      n.d.
  U02       2                    According to plan   None                                        No                       n.d.                      Progression
                                                                                                                                                    
  N03       4                    According to plan   GGT grade 2                                 No                       No                        Stable disease
  N04       4                    According to plan   ALT grade 1                                 No                       No                        Stable disease
  N05       4                    According to plan   Hemoglobin grade 3^a^                       No                       No                        Progression
                                                                                                                                                    
  N06       10                   According to plan   ALT grade 2, AST grade 1                    No                       \+                        Progression
  N07       10                   According to plan   ALT/AST grade 1, GGT grade 3                No                       No                        Progression
  U03       10                   According to plan   Fever and dyspnoe^b^                        No                       ++                        n.d.^c^
                                                                                                                                                    
  N13       12.5                 According to plan   ALT grade 1, GGT grade 2, AP grade 1        No                       No                        Progression
  N14       12.5                 Stopped on day 8    ALT/AST grade 3, GGT grade 2, LDH grade 1   Yes                      n.d.                      n.d.
  N15       12.5                 According to plan   ALT grade 2, AST grade 1, AP grade 2        No                       \+                        Progression
  N17       12.5                 According to plan   ALT/AST grade 2                             No                       No                        Progression
  U04       12.5                 According to plan   Dyspnoe                                     No                       No                        n.d.^c^
  U05       12.5                 According to plan   None                                        No                       ++                        Stable disease
                                                                                                                                                    
  N09       20                   According to plan   ALT/AST grade 2                             No                       +++                       Progression
  N10       20                   Stopped on day 8    ALT grade 4, AST grade 3, GGT grade 2       Yes                      n.d.                      n.d.
  N12       20                   Stopped on day 8    ALT grade 3, AST grade 2                    Yes                      n.d.                      n.d.^c^

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; n.d., not determined.

^a^Causal relationship with study drug unlikely.

^b^Patient U03 developed fever and dyspnoe after therapy on day 23, which was resolved with antibiotics; the patient died on day 40, causal relationship with study drug unlikely.

^c^Clinical signs of activity while on therapy including healing of cutaneous lesion (U03, U04), size reduction of lymph node metastasis (U03), and inflammatory response and softening of large tumor mass (N12).
